Historically, the primary focus of Transfusion Medicine specialists has been the immune compatibility of blood types as well as the safe and appropriate use of blood products. As a consequence of the tremendous growth in the knowledge of blood cell biology, the functions and responsibilities of Transfusion Medicine specialists have expanded to now also include the translation of cell-based therapies. Transfusion Medicine specialists are valued medical and scientific consultants to their colleagues in other disciplines, including among others surgery, cardiology, anesthesiology, neonatology, and hematology/oncology. There is a recognized need for scientific training of individuals to further advance knowledge and translation of hematopoietic cellular therapies. The overall goal of the Program in Transfusion Biology and Cellular Therapies is to prepare M.D., M.D. /Ph.D. or Ph.D. postdoctoral fellows for biomedical research careers in Transfusion Biology and Cellular Therapy. The program supports 8 postdoctoral fellow slots per year. Funding is provided for 2-3 years after which the fellows are expected to assume positions in academia or in pharmaceutical industry. The program has a broad scope of research activities. The scientific disciplines involved include Immunobiology, Hematopoiesis, and Cellular Therapy. During the first two funding periods, we have developed a multi-disciplinary program utilizing the strong clinical and basic research environments at Harvard Medical School. The major Harvard Medical School affiliated institutions participating in the training program include Children's Hospital Boston, Immune Disease Institute, Dana-Farber Cancer Institute, Brigham &Women's Hospital, and Massachusetts General Hospital. Dr. Leslie Silberstein will continue as the Program Director, and Drs. Hongbo (Robert) Luo and Judy Lieberman have been named as Co-Directors. Our approach of including rather than excluding faculty is a fundamental strength of our program and fits well with the broad nature of Transfusion Biology and Cellular Therapies and with our overall mission to facilitate cross-fertilization of clinical, basic and translational research talent. The outstanding pool of applicants and recruitment of faculty dedicated to the program has facilitated this goal. Our faculty are not only connected through this postdoctoral training program but also through other Harvard-wide, multi- institutional programs, e.g. Harvard Stem Cell Institute, the Center for Human Cell Therapy and the Dana Farber-Harvard Cancer Center. This Training Program strives to provide a unique and rich training environment for academic transfusion biology and cellular therapies.

Public Health Relevance

Historically, the primary focus of Transfusion Medicine specialists has been the immune compatibility of blood types as well as the safe and appropriate use of blood products. As a consequence of thetremendous growth in the knowledge of blood cel biology, the functions and responsibilities of Transfusion Medicine specialists have expanded to now also include consultation in the translation of cell-based therapies. This postdoctoral training program is designed to meet a recognized need for scientific training of individuals to further advance knowledge and clinical use of hematopoietic cellular therapies to treat congenital and acquired diseases.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Institutional National Research Service Award (T32)
Project #
5T32HL066987-13
Application #
8604401
Study Section
NHLBI Institutional Training Mechanism Review Committee (NITM)
Program Officer
Welniak, Lisbeth A
Project Start
2001-09-01
Project End
2017-01-31
Budget Start
2014-02-01
Budget End
2015-01-31
Support Year
13
Fiscal Year
2014
Total Cost
$1,014,889
Indirect Cost
$75,177
Name
Children's Hospital Boston
Department
Type
DUNS #
076593722
City
Boston
State
MA
Country
United States
Zip Code
02115
Dotiwala, Farokh; Mulik, Sachin; Polidoro, Rafael B et al. (2016) Killer lymphocytes use granulysin, perforin and granzymes to kill intracellular parasites. Nat Med 22:210-6
Urso, Katia; Alvarez, David; Cremasco, Viviana et al. (2016) IL4RA on lymphatic endothelial cells promotes T cell egress during sclerodermatous graft versus host disease. JCI Insight 1:
Pillai, Padmini S; Molony, Ryan D; Martinod, Kimberly et al. (2016) Mx1 reveals innate pathways to antiviral resistance and lethal influenza disease. Science 352:463-6
Gerlach, Carmen; Moseman, E Ashley; Loughhead, Scott M et al. (2016) The Chemokine Receptor CX3CR1 Defines Three Antigen-Experienced CD8 T Cell Subsets with Distinct Roles in Immune Surveillance and Homeostasis. Immunity 45:1270-1284
Martinod, K; Witsch, T; Farley, K et al. (2016) Neutrophil elastase-deficient mice form neutrophil extracellular traps in an experimental model of deep vein thrombosis. J Thromb Haemost 14:551-8
Jhunjhunwala, Siddharth; Alvarez, David; Aresta-DaSilva, Stephanie et al. (2016) Frontline Science: Splenic progenitors aid in maintaining high neutrophil numbers at sites of sterile chronic inflammation. J Leukoc Biol 100:253-60
Gavillet, Mathilde; Martinod, Kimberly; Renella, Raffaele et al. (2015) Flow cytometric assay for direct quantification of neutrophil extracellular traps in blood samples. Am J Hematol 90:1155-8
Khor, Bernard; Gagnon, John D; Goel, Gautam et al. (2015) The kinase DYRK1A reciprocally regulates the differentiation of Th17 and regulatory T cells. Elife 4:
Etulain, Julia; Martinod, Kimberly; Wong, Siu Ling et al. (2015) P-selectin promotes neutrophil extracellular trap formation in mice. Blood 126:242-6
Martinod, Kimberly; Fuchs, Tobias A; Zitomersky, Naamah L et al. (2015) PAD4-deficiency does not affect bacteremia in polymicrobial sepsis and ameliorates endotoxemic shock. Blood 125:1948-56

Showing the most recent 10 out of 73 publications